{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(2)"],"submitter":["Tanaka A"],"funding":["Astellas Pharma US"],"pubmed_abstract":["<h4>Aims</h4>To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients.<h4>Methods and results</h4>In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, a"],"journal":["European heart journal. Cardiovascular pharmacotherapy"],"pagination":["165-172"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9892869"],"repository":["biostudies-literature"],"pubmed_title":["Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial."],"pmcid":["PMC9892869"],"pubmed_authors":["Kajikawa M","Hisauchi I","Yoshiyama M","Kanbara T","Miura SI","Nasuno T","Ogata Y","Takahara K","Ohguchi S","Kitakaze M","Murohara T","Sugimoto K","Otsuka T","Fukae S","Teragawa H","Inoue T","Eguchi K","Kuroda A","Kurano M","Yamashina A","Kanda J","Yamada H","Maruhashi T","Takamori A","Shiga Y","Koikawa K","PROTECT study investigators","Machii N","Furuta M","Arimura T","Doi M","Ishihara M","Kishi H","Koyosue A","Ikehara Y","Narisawa M","Asano H","Shuto T","Ajioka M","Higashi Y","Takase B","Kitagawa K","Koga S","Uchimura Y","Hironori K","Shibata Y","Tanaka K","Uehara H","Sakuma M","Sohmiya K","Mirii J","Wakami K","Fukumoto K","Yoshida R","Ohte N","Nanasato M","Yoshida H","Bando Y","Nakano J","Kaneko T","Kanzaki Y","Izumi K","Kondo T","Nishio K","Kageyama M","Fukuda D","Yoshida Y","Nishio Y","Miyagi N","Shimabukuro M","Hirose M","Morimoto R","Kubota Y","Ako J","Oshita C","Hoshiga M","Koide Y","Umikawa M","Yasuda K","Kusunose K","Chiba S","Toyoda S","Hoshide S","Kishimoto S","Aso Y","Maeda M","Okumura T","Takenaka M","Nakamura K","Kawano H","Teruo J","Nakamura I","Node K","Ikeda S","Tanaka A","Osanai H","Toshie I","Sakamoto Y","Takemoto Y","Abe M","Nakashima Y","Kodama K","Sugiura T","Kadokami T","Nakamura R","Orita Y","Sakamoto T","Taguchi I","Suzuki S","Tokutsu A","Suzuki M","Kawabata Y","Kuriyama N","Kurozumi A","Hayashi T","Komori T","Suzuki H","Maemura K","Mori M","Ogura Y","Uemura F","Oguri M","Minami H","Sugihara M","Yagi S","Yamaguchi K","Ishizu T","Ando S","Jinnouchi H","Kabutoya T","Matsunaga K","Ohishi M","Chinen T","Sata M","Asaka M","Ueda S","Matsuhisa M","Tomiyama H","Gima Y","Kudo A","Okada Y","Ise T","Kamiya H","Hatano S","Sonoda S","Shimizu W","Kario K","Akasaki Y","Miyazaki M","Nago C"],"additional_accession":[]},"is_claimable":false,"name":"Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.","description":"<h4>Aims</h4>To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients.<h4>Methods and results</h4>In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-07-16T20:12:02.163Z","creation":"2025-04-05T23:21:23.018Z"},"accession":"S-EPMC9892869","cross_references":{"pubmed":["36308299"],"doi":["10.1093/ehjcvp/pvac059"]}}